~~<i id='4BE471551F'><strike id='4BE471551F'><tt id='4BE471551F'><pre id='4BE471551F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

fashion

author：entertainment 2025-09-30 20:06:54 - browse：3214

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： At JPM 2024, hospital systems pitch financial strength to investors

hotspot

leisure time

focus

entertainment

focus

MichaelGonzalez/APThePashaifamilyofDallasonThursdaygotsomegoodnews,butnotexactlythenewstheyhadspentt

WSS

FDA approves RSV monoclonal antibody for infants, toddlers

At JPM 2024, hospital systems pitch financial strength to investors

Arena BioWorks launches in Cambridge to speed drug discovery

A preacher's new calling: Diversifying neuroscience research

Google and Epic fight stronger regulation of AI in health care

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

explore

fashion

hotspot

Heart attack and stroke risk calculators need revising

A preacher's new calling: Diversifying neuroscience research

Continuity nursing helped my family in our darkest PICU moments

Medicare to cover more brain scans for Alzheimer’s patients

In age of alternative facts, a scholarly course on calling out crap

As digital health tech proliferates, a new institute aims to cut through hype

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

State Dept. review finds Biden bears some blame for Afghanistan failures

As digital health tech proliferates, a new institute aims to cut through hype

hotspot

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

How dance can help nurses traumatized by Covid

Custom gene therapy hints at new path for rare disease treatments

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

A preacher's new calling: Diversifying neuroscience research

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

leisure time

focus

entertainment

focus